These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 18798058)

  • 1. RAS: target for cancer therapy.
    Saxena N; Lahiri SS; Hambarde S; Tripathi RP
    Cancer Invest; 2008 Nov; 26(9):948-55. PubMed ID: 18798058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
    Blum R; Kloog Y
    Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs.
    Kohno M; Pouyssegur J
    Prog Cell Cycle Res; 2003; 5():219-24. PubMed ID: 14593716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting RAS signalling pathways in cancer therapy.
    Downward J
    Nat Rev Cancer; 2003 Jan; 3(1):11-22. PubMed ID: 12509763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.
    Lackner MR
    Expert Rev Mol Diagn; 2010 Jan; 10(1):75-87. PubMed ID: 20014924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
    Friday BB; Adjei AA
    Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress in the study of antitumor drug targeting on the Ras signaling pathway].
    Zhu YJ; Jiang FC
    Yao Xue Xue Bao; 2009 Jan; 44(1):1-10. PubMed ID: 19350814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
    Sacco E; Spinelli M; Vanoni M
    Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raf pathway inhibitors in oncology.
    Bollag G; Freeman S; Lyons JF; Post LE
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1436-41. PubMed ID: 14763129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Nat Rev Drug Discov; 2007 Jul; 6(7):541-55. PubMed ID: 17585331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel inhibitors of the PI3K family.
    Carnero A
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1265-77. PubMed ID: 19589091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
    Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
    Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New druggable targets in the Ras pathway?
    Matallanas D; Crespo P
    Curr Opin Mol Ther; 2010 Dec; 12(6):674-83. PubMed ID: 21154159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer targets in the Ras pathway.
    Rodriguez-Viciana P; Tetsu O; Oda K; Okada J; Rauen K; McCormick F
    Cold Spring Harb Symp Quant Biol; 2005; 70():461-7. PubMed ID: 16869784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
    Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
    Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
    Rotblat B; Ehrlich M; Haklai R; Kloog Y
    Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical biology of lipidated proteins.
    Triola G; Waldmann H; Hedberg C
    ACS Chem Biol; 2012 Jan; 7(1):87-99. PubMed ID: 22148864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ras signalling pathway as a target in cancer therapy.
    Graham K; Olson MF
    Recent Results Cancer Res; 2007; 172():125-53. PubMed ID: 17607939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.